-
Story
How This Former Army Officer Helps Deliver Cancer Treatments to Patients, Through Hurricanes and Beyond -
Media Release
Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan
-
Story
A Breakthrough for Patients: 25 Year Anniversary of Innovation in Treating CML -
Story
3 Ways We're Innovating Advanced Prostate Cancer Care -
Story
Exploring the Future of Cancer Care at the Time100 Health Impact Dinner -
Story
How We’re Reimagining Cancer Care for the Next Generation Patient -
Story
A Journey of Compassion: From Pharmacy to Oncology Sales -
Story
Remembering men’s health this National Veterans and Military Families Month -
Media Release
Novartis confirms unconstrained supply for Pluvicto® and continues to significantly expand the number of treatment centers
-
Media Release
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer